biostudies-literatureUnknown8(1)Taylor KIDigital health technology (DHT) tools for Parkinson's disease (PD) e.g., smartphones and wearables were used for remote and frequent measurement of motor signs in the phase 2 PASADENA study of the anti-alpha-synuclein monoclonal antibody prasinezumab. 316 early-stage PD participants were randomized to placebo, 1500 mg, or 4500 mg prasinezumab for 52 weeks; placebo participants were re-randomized to prasinezumab for the ensuing 52 weeks. Patients performed daily smartphone motor "active tests", and were passively monitored by smartphone/smartwatch throughout the day over 2 y. Change from baseline analyses censored data at dopaminergic treatment start. Bilateral speeded tapping variability and hand-turning, U-turn speed, passively monitored hand movement power, and summary Simple Sum scores NPJ digital medicine365https://www.ebi.ac.uk/biostudies/studies/S-EPMC12170883biostudies-literatureExploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.PMC12170883Remy PPopp WAbt MFang JBorngraber FGoodman IBamdadian AAnsquer SLuthra NGasser TZimmermann MBenatru IPrasinezumab Study GroupPatel PPatel NWright BBichon AEllenbogen ASpampinato UBette STaylor CHoglinger GPahwa RHoliga SManchester MPoirier ASamaniego DGibbons JKatz MDurif FFrank SVazquez IEDavid EHahn ARussell DFluchere FHoner MHui JSergo VShill HPassemard BKlos KRumpf JJDel Pozo SLMarchesi MPost ALambrecht SCorvol JCZuzuarregui RKlos SPagano GDietiker CLevy OMorrison PUmbricht DCalvas FLopez RZanigni SDebilly BSummers DNiggli MShariati NFontoura PMoro EDelfini MHPross NDeptula DPeckham EEssioux LManzanares LLPape HBenchetrit EGraziella MSchnitzler AAslam STaylor KIBarata TSchwartzbard JRukina DQuinn JDoody RVolkova-Volkmar ECosgaya MGiordana CSeppi KJanzen ASchjodt-Eriksen JMartin-Facklam MDavis TMuehlberg CStrasak AJiao JMeoni SDerost PGoubeaud MLuzy CMariani LLBoess FMarco HBBoyd Jde Toledo MGailitzky MVerselis LCorbille AGTarakad AVergnet SKremer TIsaacson SHernandez APuido MRLEickoff CMadueno SEHernandez-Vara JFries FFeigenbaum DBesharat AMultani MBritschgi MRoeben BEwert SKuhn ASiderowf AMachetanz GSchorr OMollenhauer BEbentheuer JAnandan CMartinez AGPASADENA InvestigatorsMaltete DMoon JCosson VSarry CBillnitzer AMartinez SToothaker TCastrioto AFradet AMarques ACarbone FEllmerer PBernhard FMorena JMGMarti GCzech CGasca CMacias YPalasis ADotor JPerez JCheriet SWalsh RPerez RWeber CHartmann AHuebl JHartmann CMarini KPetit AMartenyi FCatala HLevin JLipsmeier FEusebio AArrouasse RWeber SThalamus CBojarsky JKDean MHassell TLaurens BMoore EBrodsky MKobet CWegschneider MWaters CFoubert-Samier ABarbet NTanner CBardram KScelsi MAClassen JDziadek SMaass SMartinez DMColeman RRichard IDamier PEdgar CDukart JKadimi SGuimaraes-Costa RAltendorf CSriram AFraix VDahodwala NKunz MVidal TWitjas TOstrowitzki SDeuel LMartinez EBChan JNicholas ASvoboda HHauser RWurster IVogt AColeman JMurphy CDeik ALyons KVela LFernandez LCVan Blercom NCompta YPeball MKilchenmann TBonni ADavies EDiack CBega DPreterre CJankovic JDimenshteyn KCasse-Parrot CFournier MPostuma RBAndrews GHorta AHernandez AMDEggert KMMiro JUMBorroni ERascol OStaunton HBarbu SMarin JLindemann MVanegas-Arrogave NSchweyer KBaker JHoueto JLRicci BJadidi SVoglein JWeidinger EBelli SKassubek RJSink KCanelo MPoewe WD'Urso GPrasad MPerez MGBrown ECarroll CKumar RKurvits LMonnet ALitvan ILongardner KKustermann TKaminski PSchubert CFinch RSevigny JBoraud TLizarraga KStover NGorospe AGrimaldi SBoulay AMeissner WDeGiorgio JPeery TAzula JPSamier-Foubert AWenzel GAnzures-Cabrera JNikolcheva TBruecke CJoseph XTrundell DBlondeau SWeill CGruenbauer WLaganiere SKoebert JSanchez-Ferro ABrockmann KKrause PPinkhardt ELandsdall CSimuni TGrabli DMironova KCristobal GLReuther EDomenech MJMFarell MHomedes CKannenberg SPomies ECiabarra AWitt PLSalhi HRose EDelaby LKwei KSchmitt EDerkinderen PGross JZago WfalseExploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.Digital health technology (DHT) tools for Parkinson's disease (PD) e.g., smartphones and wearables were used for remote and frequent measurement of motor signs in the phase 2 PASADENA study of the anti-alpha-synuclein monoclonal antibody prasinezumab. 316 early-stage PD participants were randomized to placebo, 1500 mg, or 4500 mg prasinezumab for 52 weeks; placebo participants were re-randomized to prasinezumab for the ensuing 52 weeks. Patients performed daily smartphone motor "active tests", and were passively monitored by smartphone/smartwatch throughout the day over 2 y. Change from baseline analyses censored data at dopaminergic treatment start. Bilateral speeded tapping variability and hand-turning, U-turn speed, passively monitored hand movement power, and summary Simple Sum scores 2025-01-01T00:00:00Z2025 Jun2026-06-01T12:01:37.737Z2026-05-18T03:07:40.19ZS-EPMC121708834052392110.1038/s41746-025-01572-8